Department of Chemistry and Research Institute of Basic Sciences, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Korea.
J Mater Chem B. 2021 Jan 28;9(3):824-831. doi: 10.1039/d0tb02529a.
Successful applications of photodynamic therapy (PDT) in cancer treatment require the development of effective photosensitizers with controllable singlet oxygen generation. Here we report a ubiquinone-BODIPY photosensitizer that self-assembles into nanoparticles (PS-Q-NPs) and undergoes selective activation and deaggregation within the highly reductive intracellular environment of tumor cells. PS-Q-NPs are highly stable in aqueous buffer solution, and exhibit minimal fluorescence and photosensitization due to a rapid non-radiative relaxation process. Upon endocytosis by cancer cells, reduction of the ubiquinone moiety by intracellular glutathione (GSH) triggers the conversion of the aggregated hydrophobic precursor into the active hydrophilic carboxylate derivative PS-A. The conversion results in enhanced fluorescence and therapeutic singlet oxygen generation, portending to its application as an activatable photosensitizer for fluorescence imaging-guided photodynamic cancer therapy.
光动力疗法(PDT)在癌症治疗中的成功应用需要开发具有可控单线态氧生成的有效光敏剂。在这里,我们报告了一种泛醌-BODIPY 光敏剂,它可以自组装成纳米颗粒(PS-Q-NPs),并在肿瘤细胞内高度还原的细胞环境中选择性激活和去聚集。PS-Q-NPs 在水缓冲溶液中高度稳定,由于快速的非辐射弛豫过程,表现出最小的荧光和光致发光。当被癌细胞内吞后,细胞内谷胱甘肽(GSH)还原泛醌部分触发了聚集的疏水性前体向活性亲水性羧酸衍生物 PS-A 的转化。这种转化导致荧光和治疗性单线态氧生成增强,预示着它可以作为一种可激活的光敏剂,用于荧光成像引导的光动力癌症治疗。